MedPath

Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer

Not Applicable
Completed
Conditions
Radiation Toxicity
Oral Complications of Chemotherapy and Head/Neck Radiation
Radiation-Induced Xerostomia
Head and Neck Cancer
Registration Number
NCT02589938
Lead Sponsor
Wake Forest University Health Sciences
Brief Summary

This study is being done to find out what effects, good and/or bad, acupuncture has on participants and their xerostomia caused by radiation therapy for the treatment of the cancer.

Detailed Description

Patients who have met all eligibility criteria will be randomized to standard oral hygiene, standard oral hygiene + true acupuncture twice weekly for 4 weeks, or standard oral hygiene + sham acupuncture twice weekly for 4 weeks by a form of adaptive randomization, called minimization, because simple randomization could result in covariate imbalances .

The acupuncture points will be at three sites on each ear (Shenmen, Point Zero, Salivary Gland 2-prime), a site on the chin (CV24), a site on each forearm (Lu7), a site on each hand (LI 1-prime), a site on each leg (K6), and one placebo needle at Gb32 for a total of 14 sites. All sites will be applied for 20 minutes. For body points, standardized techniques for location will be utilized, which are based on anatomical landmarks as well as proportional measurements using the patient's own body. For example, finger breadth is based on each patient's middle finger, and the proportional unit of measure, the "cun," is defined as the distance between the two medial ends of the creases of the interphalangeal joints when the middle finger is flexed. Earpoint locations will mimic standard practice and be identified by the acupuncturists.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
230
Inclusion Criteria
  • Must be at least 18 years of age and able to give informed consent.

  • Must be able to read, write and understand English.

  • Must have a diagnosis of head/neck cancer.

  • Must have received bilateral radiation therapy, and subsequently developed grade 2 or 3 xerostomia, according to modified RTOG scale:

    • Grade 0 - None
    • Grade 1 - Slight dryness of mouth (good response on stimulation and no significant dietary alterations necessary)
    • Grade 2 - Moderate dryness of mouth (poor response on stimulation and altered oral intake required such as frequent water, oral lubricants, or soft-moist foods)
    • Grade 3 - Complete dryness of mouth (no response on stimulation and difficult oral alimentation; IV fluids, pureed diet or tube feedings may be required)
    • Grade 4 - Fibrosis
  • Must have received external beam radiation at a mean dose of at least 24 Gy to one of the parotid glands. The other gland can receive less than 24 Gy.

  • Must have completed radiotherapy at least 12 months prior to entry.

  • Must have anatomically intact parotid and submandibular glands. A focused (head/neck) history and exam conducted by a physician or dentist within the past year is required.

  • Must be acupuncture naïve.

  • Must have ECOG performance status of 0-2.

Exclusion Criteria
  • History of xerostomia, Sjogren's disease or other illness known to affect salivation prior to head/neck radiation.
  • Suspected or known closure of salivary gland ducts on either side. (Patients addressed in inclusion criteria (i.e. those who have had one submandibular gland removed) are expected to have closure to the removed submandibular gland and will be exempt from this exclusion criteria.)
  • Currently receiving or planning to use drugs, herbs, alternative medicines, or devices that could affect salivary production. Treatment known to affect salivation should be stopped at least 14 days prior to enrollment. Over the counter products used for salivary substitution are allowed, but will need to be discontinued for at least 24 hours prior to saliva and questionnaire data collection.
  • Have received any investigational new drug within the past 30 days or planning to receive such during the study period.
  • Active systemic infection or skin infection at or near the acupuncture sites.
  • Receiving chemotherapy during study period.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Xerostomia Questionnaire ScoresBaseline to 4, 8, 12, 26 weeks post acupuncture

Self reported Xerostomia questionnaire consists of eight items (scored on an 11-point scale; 0-10), has been validated in several cohorts, and is regarded as the gold-standard measure for xerostomia.The questions are equally divided into 4 items about oral dryness while eating or chewing and 4 items about dryness while not eating or chewing. Item scores are summed and transformed linearly to produce a final summary score between 0 and 80. Higher scores represent more xerostomia. Questionnaire is completed prior to randomization and at each time point week 4, week 8, week 12, and end of study.

Secondary Outcome Measures
NameTimeMethod
Functional Assessment of Cancer Therapy (FACT-G) TotalBaseline, 4 , 8 , 12, and 26 weeks

The FACT-G QOL instrument discriminates between individuals with metastatic and non-metastatic disease, as well as between patients at different stages of illness. The scale has good concurrent validity, high internal consistency (0.89), and good test-re-test reliability (0.82 to 0.88). The total score is reported, which is a combination of the subscales of physical, social/family, emotional, and functional well-being, with higher scores representing better QOL. Scale range 0-108

The Acupuncture Expectancy Scale (AES)Week 4

The 4-item AES was used to ensure there were no baseline group differences in expectations related to the benefits of acupuncture on dry mouth and to assess aspects of blinding after the first 4 weeks of acupuncture for the TA and SA groups. The AES is reliable (α=0·82) and valid by positive correlation with patient self-reported efficacy and satisfaction. The scale has been further validated among cancer patients who were acupuncture naïve. Scale from 4-20.

Trial Locations

Locations (36)

Providence Saint Joseph Medical Center/Disney Family Cancer Center

🇺🇸

Burbank, California, United States

Kaiser Permanente-San Francisco

🇺🇸

San Francisco, California, United States

Kaiser Permanente-Santa Teresa-San Jose

🇺🇸

San Jose, California, United States

Kaiser Permanente-San Rafael

🇺🇸

San Rafael, California, United States

Kaiser San Rafael-Gallinas

🇺🇸

San Rafael, California, United States

Kaiser Permanente Medical Center - Santa Clara

🇺🇸

Santa Clara, California, United States

Kaiser Permanente-Santa Rosa

🇺🇸

Santa Rosa, California, United States

Kaiser Permanente-South San Francisco

🇺🇸

South San Francisco, California, United States

Kaiser Permanente-Walnut Creek

🇺🇸

Walnut Creek, California, United States

Queen's Medical Center

🇺🇸

Honolulu, Hawaii, United States

Scroll for more (26 remaining)
Providence Saint Joseph Medical Center/Disney Family Cancer Center
🇺🇸Burbank, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.